Erenumab in chronic migraine with medication overuse:Subgroup analysis of a randomized trial by Tepper, Stewart J. et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Erenumab in chronic migraine with medication overuse
Subgroup analysis of a randomized trial
Tepper, Stewart J.; Diener, Hans Christoph; Ashina, Messoud; Brandes, Jan Lewis;
Friedman, Deborah I.; Reuter, Uwe; Cheng, Sunfa; Nilsen, Jon; Leonardi, Dean K.; Lenz,
Robert A.; Mikol, Daniel D.
Published in:
Neurology
DOI:
10.1212/WNL.0000000000007497
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC-ND
Citation for published version (APA):
Tepper, S. J., Diener, H. C., Ashina, M., Brandes, J. L., Friedman, D. I., Reuter, U., ... Mikol, D. D. (2019).
Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurology,
92(20), E2309-E2320. https://doi.org/10.1212/WNL.0000000000007497
Download date: 27. May. 2020
ARTICLE OPEN ACCESS CLASS OF EVIDENCE
Erenumab in chronic migraine with medication
overuse
Subgroup analysis of a randomized trial
Stewart J. Tepper, MD, Hans-Christoph Diener, MD, PhD, Messoud Ashina, MD, PhD, Jan Lewis Brandes, MD,
Deborah I. Friedman, MD, MPH, Uwe Reuter, MD, Sunfa Cheng, MD, Jon Nilsen, PhD, Dean K. Leonardi, PhD,
Robert A. Lenz, MD, PhD, and Daniel D. Mikol, MD, PhD
Neurology® 2019;92:e2309-e2320. doi:10.1212/WNL.0000000000007497
Correspondence
Dr. Tepper
sjtepper@gmail.com
Abstract
Objective
To determine the effect of erenumab, a human anti-calcitonin gene-related peptide receptor
monoclonal antibody, in patients with chronic migraine and medication overuse.
Methods
In this double-blind, placebo-controlled study, 667 adults with chronic migraine were ran-
domized (3:2:2) to placebo or erenumab (70 or 140 mg), stratified by region and medication
overuse status. Data from patients with baseline medication overuse at baseline were used to
assess changes in monthly migraine days, acute migraine-specific medication treatment days,
and proportion of patients achieving ≥50% reduction from baseline in monthly migraine days.
Results
Of 667 patients randomized, 41% (n = 274) met medication overuse criteria. In the medication
overuse subgroup, erenumab 70 or 140 mg groups had greater reductions than the placebo
group at month 3 in monthly migraine days (mean [95% confidence interval] −6.6 [−8.0 to
−5.3] and −6.6 [−8.0 to −5.3] vs −3.5 [−4.6 to −2.4]) and acute migraine-specific medication
treatment days (−5.4 [−6.5 to −4.4] and −4.9 [−6.0 to −3.8] vs −2.1 [−3.0 to −1.2]). In the
placebo and 70 and 140 mg groups, ≥50% reductions in monthly migraine days were achieved
by 18%, 36% (odds ratio [95% confidence interval] 2.67 [1.36–5.22]) and 35% (odds ratio 2.51
[1.28–4.94]). These clinical responses paralleled improvements in patient-reported outcomes
with a consistent benefit of erenumab across multiple measures of impact, disability, and health-
related quality of life. The observed treatment effects were similar in the non–medication
overuse subgroup.
Conclusions
Erenumab reduced migraine frequency and acute migraine-specific medication treatment days in
patients with chronic migraine and medication overuse, improving disability and quality of life.
Clinicaltrials.gov identifier
NCT02066415.
Classification of evidence
This study provides Class II evidence that erenumab reduces monthly migraine days at 3
months in patients with chronic migraine and medication overuse.
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Class of Evidence
Criteria for rating
therapeutic and diagnostic
studies
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Patients with chronic migraine (CM) are a difficult-to-treat
population.1 In an attempt to manage their symptoms,
patients with CM commonly overuse acute medications, in-
cluding simple and combination analgesics, triptans, and
opioids.2,3 Such medication overuse is a risk factor for
chronification4,5 and can lead to medication overuse head-
ache.6 Medication overuse is defined by excessive use of
medications to treat acute symptoms of migraine and is not
based on a diagnosis of medication overuse headache, which is
a secondary headache disorder.
Patients with CM and medication overuse represent a pop-
ulation with a high unmet need. Debated treatment
approaches include withdrawal from the implicated acute
treatment, initiation of a preventive treatment, or both.7–9 It
remains unclear whether migraine preventive treatments can
reduce acute medication use or lower the risk of medication
overuse headache.
Erenumab (in the United States, erenumab-aooe) is a fully
human anti-calcitonin gene-related peptide (CGRP) re-
ceptor monoclonal antibody approved for migraine pre-
vention10 with demonstrated clinically relevant efficacy in
CM.11 CGRP is implicated in migraine pathophysiology,
and its levels are elevated in CM.12–14 A 3-month pivotal
trial in CM prevention demonstrated reduced monthly
migraine days (MMD) for both 70- and 140-mg erenumab
dose groups and reduced acute medication use, including
migraine-specific medications (triptans, ergot deriva-
tives).15 Here, we report the results of a planned subgroup
analysis of a hard-to-treat patient population, those with and
without medication overuse (a study stratification factor),
using data from a pivotal study of erenumab prevention in
patients with CM.
Methods
The objective of this subgroup analysis was to assess the ef-
ficacy of erenumab in patients with CM in the presence and
absence of medication overuse. This study provided Class II
evidence of efficacy as assessed by reduction in MMD, re-
duction in acute migraine-specific medication use, and
improvements in patient-reported outcomes (PROs).
Patients and data source
This was a preplanned exploratory analysis of a pivotal study
that evaluated efficacy and safety of erenumab in patients with
CM (≥15 headache days per month, of which ≥8 were
migraine days). The eligibility criteria, design, and primary
results of the parent study were previously published.15
Patients with opioid overuse (>12 days during the 3 months
before screening or >4 days during baseline) were excluded
from the study, and migraine preventive drugs were pro-
hibited during the study and 2 months before baseline. The
study comprised 667 participants randomized at 69 study sites
worldwide.
Patients were randomized to 1 of 3 treatment arms in a 3:2:2
ratio (subcutaneous placebo, erenumab 70 mg, or erenumab
140 mg monthly [daily]), stratified by region (North America
vs other) and medication overuse (yes or no) for a 3-month
double-blind treatment phase.
This analysis used data from patients with and without
medication overuse based on frequency of acute headache
medication intake during the baseline period, defined with
strict criteria according to International Headache Society
guidelines for CM clinical trials and similar to those previously
used in a study of onabotulinumtoxinA.16,17 Briefly, medica-
tion overuse was defined as use of simple analgesics (non-
narcotic analgesics such as acetaminophen or nonsteroidal
anti-inflammatory drugs) for ≥15 days (>3 d/wk in each week
with at least 5 diary days), triptans for ≥10 days (>2 d/wk in
each week with at least 5 diary days), or combination therapy
(any combination of triptans, ergot derivatives, analgesics, or
simple analgesics with opiates or butalbital) for ≥10 days (>3
d/wk in each week with at least 5 diary days) per month. This
classification of medication overuse should not be interpreted
as confirming a secondary diagnosis of medication overuse
headache.
Standard protocol approvals, registrations,
and patient consents
The study was approved by an independent ethics committee
or local institutional review board at each participating site,
and written informed consent was obtained from all enrolled
patients. The study was conducted in accordance with the
International Conference on Harmonisation Tripartite
Guideline on Good Clinical Practice. This study was regis-
tered at Clinicaltrials.gov (NCT02066415).
Outcome measures
We conducted efficacy assessments throughout the baseline
and double-blind phases of the study, with key assessments at
month 3 (during the last month of double-blind treatment
phase). Patients used a daily electronic diary (eDiary) to re-
port information about their migraine and nonmigraine
Glossary
AE = adverse event; CGRP = calcitonin gene-related peptide; CI = confidence interval; CM = chronic migraine; eDiary =
electronic diary; HIT-6 = Headache Impact Test; HRQOL = health-related quality of life; MIDAS = Migraine Disability
Assessment;MMD = monthly migraine days;MSQ = Migraine-Specific Quality-of-Life Questionnaire; PREEMPT = Phase 3
Research Evaluating Migraine Prophylaxis Therapy; PRO = patient-reported outcome.
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headaches, acute medication use, and PROs (including,
Headache Impact Test [HIT-6],18,19 Migraine Disability As-
sessment [MIDAS; measured as 4-week recall period vs
3-month recall of standard MIDAS],20 and Migraine-Specific
Quality-of-Life Questionnaire [MSQ]).21,22 Efficacy end-
points for the subgroup analysis included changes in MMD,
changes in acute migraine-specific medication days, pro-
portion of patients achieving ≥50% reduction in MMD, PRO
measures (MSQ, HIT-6, MIDAS), and proportion of patients
changing status from medication overuse to nonoveruse sta-
tus. We evaluated safety by monitoring adverse events (AEs)
(with MedDRA version 19.0),23 serious AEs,24 laboratory
assessments, vital signs, ECGs, and anti-erenumab antibodies.
Statistical analysis
All patients who received at least 1 dose of study drug and
completed at least 1 postbaseline monthly eDiary measure-
ment were included in the intent-to-treat analysis. Descriptive
summaries are provided for efficacy outcomes. Adjusted
analyses of efficacy outcomes used a generalized linear mixed
model including treatment, visit, treatment-by-visit in-
teraction, region stratification factor, and baseline value as
covariates and assuming a first-order autoregressive co-
variance structure. Values of p were not adjusted for multiple
comparisons. Analyses of medication overuse by visit and
patient reported outcome measures by medication overuse
subgroup were post hoc.
Data availability
Qualified researchers may request data from Amgen clinical
studies. Complete details are available at amgen.com/
datasharing.
Results
Patients
Of 667 patients randomized, 41% (n = 274) met the criteria
for medication overuse. At baseline, a few differences between
the medication overuse and nonoveruse subgroups were ob-
served (table 1). The percentage of patients with prior
treatment failure with at least 1 preventive treatment was
higher in the medication overuse subgroup (75% vs 63%;
table 1). The mean (SD) baseline MMD was 19.0 (4.5) days
in the medication overuse subgroup and 17.3 (4.6) days in the
nonoveruse subgroup. Although there was almost no differ-
ence in the percentage of patients using acute headache
medications, the percentage of patients using acute migraine-
specific medications was higher in the medication overuse
subgroup (92% vs 68%; table 1), as was the mean number of
days of monthly acute migraine-specific medication use
(table 1).
Outcomes
Mean MMD with and without medication overuse
At month 3, the reduction in MMD was greater in the ere-
numab groups than in the placebo group in both the
medication overuse and non–medication overuse subgroups
(figure 1). The least-squares mean (95% confidence interval
[CI]) change from baseline in MMD in the non–medication
overuse placebo group was −4.7 (−5.5 to −3.8) vs −6.7 (−7.8
to −5.7) in both the erenumab 70 mg and 140 mg groups,
representing treatment differences of −2.0 (−3.4 to −0.7).
Respective MMD changes in the medication over use sub-
group were −3.5 (−4.6 to −2.4) vs −6.6 (−8.0 to −5.3) for both
erenumab doses, with treatment differences of −3.1 (−4.8
to −1.4).
≥50% Responder rates with and without medication
overuse
The percentage of patients achieving ≥50% reductions in
MMDwas greater in the erenumab groups than in the placebo
group in both the medication overuse and non–medication
overuse subgroups (figure 1). In the nonoveruse subgroup,
the ≥50% responder rates were 27% (placebo) vs 42% (70 mg
odds ratio [95% CI] 1.95 [1.17–3.23]) and 46% (140 mg OR
2.25 [1.36–3.74]). In the medication overuse subgroup, the
respective ≥50% responder rates were 18% (placebo) vs 36%
(70 mg OR 2.67 [1.36–5.22]) and 35% (140 mg OR 2.51
[1.28–4.94]).
Acute migraine-specific medication use days with and
without medication overuse
Reduction in acute migraine-specific medication use days was
greater in the erenumab groups than in the placebo group in
both the medication overuse and nonoveruse subgroups
(figure 2). Compared with a least-squares mean (95% CI)
change from baseline in acute migraine-specific medication
use of −1.2 (−1.7 to −0.8) days in the non–medication
overuse placebo group, the change in acute migraine-specific
medication use was −2.1 (−2.7 to −1.5) days vs −3.6 (−4.2 to
−3.0) days in the erenumab 70 mg or 140 mg groups, re-
spectively. The treatment differences were −0.9 (−1.6 to −0.1)
(70 mg) and −2.4 (−3.2 to −1.6) (140 mg). The respective
changes in acute migraine-specific medication use days in the
medication overuse subgroup were −2.1 (−3.0 to −1.2) vs
−5.4 (−6.5 to −4.4) and −4.9 (−6.0 to −3.8) with treatment
differences of −3.3 (−4.7 to −1.9) (70 mg) and −2.8 (−4.2 to
−1.4) (140 mg).
Transition from medication overuse to nonoveruse
Erenumab treatment reduced the number of patients with
overuse of acute migraine medication intake (figure 3 and
table 2). Of patients who overused simple analgesics at
baseline, 60% (15 of 25) in the 70 mg group and 71% (24 of
34) in the 140 mg group transitioned to nonoveruse status at
month 3, compared with 52% (23 of 44) of patients in the
placebo group. Of patients who overused triptans at baseline,
65% (61 of 94) in the 70 mg group and 54% (52 of 96) in the
140 mg group changed to nonoveruse status at month 3,
compared with 33% (42 of 127) of patients in the placebo
group. Of patients who overused combination therapy at
baseline, 45% (47 of 105) in the 70 mg group and 59% (66 of
112) in the 140 mg group changed to nonoveruse status at
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Table 1 Demographics and baseline disease characteristics
Without medication overuse Medication overuse
Placebo
(N = 169)
Erenumab 70 mg
(N = 112)
Erenumab 140 mg
(N = 112)
Total
(N = 393)
Placebo
(N = 117)
Erenumab 70 mg
(N = 79)
Erenumab 140 mg
(N = 78) Total (N = 274)
Age, y 40.8 (11.8) 41.1 (11.5) 42.2 (11.1) 41.3 (11.5) 43.9 (10.4) 41.8 (11.2) 44.1 (10.3) 43.4 (10.8)
Female, n (%) 136 (81) 92 (82) 91 (81) 319 (81) 90 (77) 74 (94) 69 (89) 233 (85)
White, n (%) 156 (92) 100 (89) 108 (96) 364 (93) 112 (96) 76 (96) 76 (97) 264 (96)
History of prior prophylactic failure,a n (%)
Never failed preventive medication 57 (34) 46 (41) 43 (38) 146 (37) 29 (25) 18 (23) 21 (27) 68 (25)
Failed ≥1 preventive medications 112 (66) 66 (59) 69 (62) 247 (63) 88 (75) 61 (77) 57 (73) 206 (75)
Failed ≥2 preventive medications 79 (47) 48 (43) 52 (46) 179 (46) 63 (54) 45 (57) 40 (51) 148 (54)
Acute headache medication use at baseline, n (%) 165 (98) 112 (100) 110 (98) 387 (99) 117 (100) 79 (100) 78 (100) 274 (100)
Migraine specific 114 (68) 71 (63) 81 (72) 266 (68) 111 (95) 72 (91) 68 (87) 251 (92)
Not migraine specific 143 (85) 98 (88) 96 (86) 337 (86) 103 (88) 69 (87) 65 (83) 237 (87)
Baseline period
Monthly migraine days 17.4 (4.7) 17.3 (4.2) 17.1 (4.7) 17.3 (4.6) 19.5 (4.5) 18.6 (4.6) 18.8 (4.5) 19.0 (4.5)
Monthly migraine attacks 4.5 (1.6) 4.6 (1.5) 4.4 (1.6) 4.5 (1.6) 3.9 (1.9) 4.5 (1.9) 4.2 (1.6) 4.1 (1.8)
Monthly headache days 20.4 (4.1) 19.9 (3.7) 20.2 (4.0) 20.2 (3.9) 22.1 (3.5) 21.3 (3.8) 21.5 (3.5) 21.7 (3.6)
Monthly acute migraine-specific medication use days 6.5 (6.3) 6.3 (6.4) 7.3 (6.1) 6.7 (6.3) 13.7 (7.3) 12.2 (6.7) 13.1 (6.9) 13.1 (7.0)
Abbreviation: N = number of patients randomized.
Data represent mean (SD) unless otherwise indicated.
a Failure due to lack of efficacy or poor tolerability.
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Figure 1 Change from baseline in MMD over time
Least-squares mean (LSM) changes
from baseline in monthly migraine
days (MMD) in patients (A) without
and (B) with medication overuse
among patients with chronic mi-
graine (CM) who were assigned to
receive placebo, erenumab 70mg, or
erenumab 140 mg every month. Er-
ror bars represent 95% confidence
intervals (CIs). *p < 0.005, **p < 0.001
for erenumab vs placebo. Proportion
of patients (C) without and (D) with
medication overuse who achieved
≥50% change from baseline in MMD
among patients with CM who were
assigned to receive placebo, erenu-
mab 70 mg, or erenumab 140 mg
every month.
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month 3, compared with 40% (70 of 176) of patients in the
placebo group. Similar results were found when we assessed
nonoveruse status over the full 3 months or over the last 2
months (table 2). More than half of the erenumab-treated
patients who overused simple analgesics or triptans at baseline
switched to nonoveruse status by month 1 (table 2). Of the 35
erenumab-treated patients who switched to nonoveruse of
simple analgesics by month 1, 30 (86%) maintained non-
overuse status through all 3 months. Of the 112 erenumab-
treated patients who switched to nonoveruse of triptans by
month 1, 78 (70%) maintained nonoveruse status through all
3 months. Of the 78 erenumab-treated patients who switched
to nonoveruse of combination therapy by month 1, 49 (63%)
maintained nonoveruse status through all 3 months.
Patient-reported outcomes
In the both subgroups, mean reduction (improvement)
from baseline in total HIT-6 score was greater in the ere-
numab groups compared with the placebo group (table 3).
Treatment difference for change in HIT-6 score at month 3
exceeded the established group-level minimally important
difference for HIT-6 total score (≥2.3-point reduction).
Reductions from baseline to month 3 in MIDAS total scores
were greater in the erenumab groups compared with the
placebo group, indicating greater improvement. Differences
from baseline in MIDAS total score were >5 days, indicative
of a clinically meaningful change.25 Health-related quality of
life (HRQOL) was measured by the change in MSQ scores
from baseline. At month 3, changes from baseline were
greater in the erenumab groups compared with the placebo
group in each MSQ domain score in the non–medication
overuse subgroup and in the medication overuse subgroup
(table 3). The observed between-treatment-group differ-
ences exceeded the respective minimally important differ-
ence for the MSQ Role Function–Restrictive (≥3.2) and
MSQ Emotional Functioning (≥7.5) domain scores in both
the non–medication overuse and medication overuse
subgroups.
Adverse events
The safety profile and AE frequency in the full patient pop-
ulation were previously reported.15 The frequency of AEs was
similar among treatment groups and between the medication
overuse and non–medication overuse subgroups, and most
AEs reported were mild or moderate in severity (table 4). The
most frequent AEs reported for the erenumab-treated patients
(≥2% of erenumab-treated patients) were injection site ery-
thema, muscle spasms, migraine, injection site pain,
Figure 2 Change from baseline in acute migraine-specific medication treatment days over time
Least-squares mean (LSM) changes from baseline in acute migraine-specific medication treatment days in patients (A) without and (B) with medication
overuse among patients with chronic migraine who were assigned to receive placebo, erenumab 70 mg, or erenumab 140 mg every month. Error bars
represent 95% confidence intervals (CIs). *p < 0.05, **p < 0.001 for erenumab vs placebo.
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constipation, cough, oropharyngeal pain, upper respiratory
tract infection, nausea, and nasopharyngitis.
Discussion
Patients with CM who overuse acute headache medications
are often difficult to treat and represent a large unmet need
commonly encountered in clinical practice. Patients in this
study were stratified by medication overuse on the basis of
a daily eDiary completed over the 4-week baseline period in
which frequency counts of acute medication intake were
recorded (and should not be interpreted as having a con-
firmed secondary headache diagnosis of medication overuse
headache). More than 40% of the patients in this study had
medication overuse during the baseline period, lower than the
estimated 68% to 75% of patients with CM as previously
reported in a recent clinic-based study and the Phase 3 Re-
search Evaluating Migraine Prophylaxis Therapy (PRE-
EMPT) trials of onabotulinumtoxinA for CM prevention and
the European topiramate CM prevention study3,16,26,27 but
similar to 37% observed in the US topiramate CM prevention
study.27,28
In both the medication overuse and non–medication overuse
subgroups, erenumab treatment resulted in a significant clinical
response with a larger reduction in MMD and acute migraine-
specific medication treatment days and a larger percentage of
patients achieving a ≥50% response rate compared with pla-
cebo. The treatment differences appeared to be greater in the
medication overuse subgroup than in the non–medication
overuse subgroup; however, the absolute treatment effect was
the same between the 2 groups. The placebo response was
lower in the medication overuse subgroup, resulting in an odds
ratio of achieving a ≥50% response comparable to or slightly
higher than that of the non–medication overuse group. Even
though all patients did not achieve this clinical endpoint, it is
important to note that the ≥50% response, widely accepted by
clinicians, is an arbitrary threshold and does not represent all
patients who had a clinical improvement. In a separate analysis
from this study, we showed that although ≈40% of patients
achieved a ≥50% response, ≈50% to 60% achieved clinically
meaningful changes in PRO scores.29 This was similar to the
PREEMPT studies with onabotulinumtoxinA in which 27% of
treated participants had a ≥ 5-point reduction in HIT-6 score
and a ≥50% reduction in headache days.30 Thus, a reduction in
severity of a migraine may be sufficient to improve the quality
of life for patients, which would not necessarily be reflected in
the 50% responder rate data. However, even then not all
patients may respond to treatments that are highly effective in
other patients.
Regardless of the causal effect of medication overuse in mi-
graine prevention, CM with medication overuse represents
a severe form of migraine and can be difficult to treat.31 In this
study, the medication overuse subgroup had a higher use of
preventive medications at baseline and a higher percentage
who failed to respond to 1 or 2 prior preventive treatments,
indicative of a more severe subgroup of patients.
To more completely understand the clinical meaningfulness
of new therapeutics for a chronic disease, it is necessary to
assess outcomes of measures of efficacy, safety, and HRQOL
in patients with potentially different responses to therapy. The
clinical responses observed in this subgroup analysis paral-
leled improvements in PROs with a consistent benefit of
erenumab across multiple measures of impact (HIT-6), dis-
ability (MIDAS), and HRQOL (MSQ). These data demon-
strate that the rapid reductions in migraine frequency are
accompanied by early improvements in ability to perform
daily activities and lessened feelings of hopelessness or frus-
tration or impact of CM.
Figure 3 Proportion of patients with medication overuse at baseline who changed status to non–medication overuse at
month 3, by acute medication category
Medication overuse defined as ≥15 days of simple
analgesics (nonnarcotic analgesics such as acet-
aminophen or nonsteroidal anti-inflammatory
drugs), ≥10 days of triptans, and ≥10 days of com-
bination therapy (any combination of triptans, er-
got derivatives, analgesics, or simple analgesics
with opiates or butalbital) per month.
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Table 2 Proportion of patients transitioning frommedication overuse to non–medication overuse status by medication
category
Medication overuse
Placebo (N = 113) Erenumab 70 mg (N = 77) Erenumab 140 mg (N = 78)
Simple analgesics, N1 44 25 34
Month 1, n (%) 22 (50.0) 13 (52.0) 22 (64.7)
Month 2, n (%) 24 (54.5) 15 (60.0) 25 (73.5)
Month 3, n (%) 23 (52.3) 15 (60.0) 24 (70.6)
Over months 2–3, n (%) 27 (61.4) 16 (64.0) 26 (76.5)
Over months 1–3, n (%) 25 (56.8) 17 (68.0) 27 (79.4)
Odds ratio (95% CI) 1.4 (0.5–3.9) 2.9 (1.1–7.9)
p Value 0.59 0.03
All 3 mo,a n (%) 16 (36.4) 11 (44.0) 19 (55.9)
Odds ratio (95% CI) 1.2 (0.4–3.3) 2.3 (0.9–5.7)
p Value 0.73 0.075
Triptans, N1 127 94 96
Month 1, n (%) 37 (29.1) 58 (61.7) 54 (56.3)
Month 2, n (%) 38 (29.9) 54 (57.4) 57 (59.4)
Month 3, n (%) 42 (33.1) 61 (64.9) 52 (54.2)
Over months 2–3, n (%) 43 (33.9) 60 (63.8) 57 (59.4)
Over months 1–3, n (%) 41 (32.3) 61 (64.9) 56 (58.3)
Odds ratio (95% CI) 3.9 (2.2–6.9) 2.9 (1.7–5.1)
p Value <0.001 <0.001
All 3 mo,a n (%) 22 (17.3) 38 (40.4) 40 (41.7)
Odds ratio (95% CI) 3.2 (1.7–6.0) 3.3 (1.8–6.0)
p Value <0.001 <0.001
Combination, N1 176 105 112
Month 1, n (%) 44 (25.0) 32 (30.5) 46 (41.1)
Month 2, n (%) 58 (33.0) 46 (43.8) 54 (48.2)
Month 3, n (%) 70 (39.8) 47 (44.8) 66 (58.9)
Over months 2–3, n (%) 58 (33.0) 49 (46.7) 67 (59.8)
Over months 1–3, n (%) 55 (31.3) 48 (45.7) 59 (52.7)
Odds ratio (95% CI) 1.8 (1.1–3.0) 2.5 (1.6–4.1)
p Value 0.02 <0.001
All 3 mo,a n (%) 32 (18.2) 17 (16.2) 32 (28.6)
Odds ratio (95% CI) 0.9 (0.5–1.7) 1.9 (1.1–3.3)
p Value 0.67 0.03
Abbreviations: CI = confidence interval; n, number of patients who converted to nonoveruser at postbaseline assessment; N = number of patients who
received at least 1 dose of study drug and completed at least 1 postbaseline monthly electronic diary measurement; N1, number of patients who were
medication overusers at baseline in the corresponding medication category; % = n/N1;.
a Patients were nonoverusers in each of the 3 months of the double-blind treatment phase.
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Table 3 Patient-reported outcomes at month 3 in patients with chronic migraine by baseline medication overuse status
Without medication overuse Medication overuse
Placebo (N = 168) Erenumab 70 mg (N = 111) Erenumab 140 mg (N = 109) Placebo (N = 113) Erenumab 70 mg (N = 77) Erenumab 140 mg (N = 78)
HIT-6 total score (range: 36–78)
Baseline score, mean (SD) 63.0 (5.3) 63.0 (5.4) 62.2 (6.2) 63.8 (5.0) 63.9 (4.4) 63.3 (4.8)
Change from baseline −3.4 (−4.4 to −2.3) −6.0 (−7.2 to −4.6) −5.8 (−7.1 to −4.6) −2.9 (−4.1 to −1.7) −5.2 (−6.7 to −3.7) −5.4 (−6.9 to −3.9)
Difference from placebo −2.6 (−4.2 to −1.0) −2.5 (−4.1 to −0.8) −2.3 (−4.2 to −0.3) −2.5 (−4.4 to −0.6)
p Value 0.002 0.003 0.021 0.011
MIDAS total score
Baseline score, mean (SD) 65.5 (58.2) 63.3 (47.5) 56.8 (49.4) 71.6 (52.7) 69.3 (43.4) 66.6 (55.7)
Change from baseline −11.2 (−17.0 to −5.5) −18.4 (−25.2 to 11.6) −23.5 (−30.3 to −16.6) −3.6 (−12.0 to 4.8) −22.0 (−32.0 to −12.1) −16.1 (−26.1 to −6.1)
Difference from placebo −7.2 (−16.1 to 1.7) −12.2 (−21.1 to −3.3) −18.5 (−31.4 to −5.5) −12.5 (−25.4 to 0.4)
p Value 0.11 0.007 0.005 0.058
MSQ-RFR (range 0–100)
Baseline score, mean (SD) 43.8 (17.7) 46.0 (19.4) 46.8 (20.3) 41.3 (17.4) 42.9 (16.5) 43.7 (17.3)
Change from baseline 12.0 (9.0–15.1) 18.4 (14.7–22.1) 20.6 (16.8–24.3) 11.7 (8.0–15.4) 17.1 (12.6–21.5) 17.4 (13.0–21.9)
Difference from placebo 6.4 (1.6–11.2) 8.5 (3.7–13.3) 5.4 (−0.4 to 11.2) 5.7 (0.0–11.51)
p Value 0.009 <0.001 0.069 0.051
MSQ-RFP (range 0–100)
Baseline score, mean (SD) 59.9 (1.6) 60.6 (2.1) 64.2 (2.1) 60.8 (19.5) 63.8 (21.6) 61.1 (20.0)
Change from baseline 10.0 (7.3–12.7) 14.2 (11.0–17.5) 16.7 (13.4–20.0) 7.7 (4.4–11.1) 11.6 (7.6–15.6) 10.5 (6.5–14.4)
Difference from placebo 4.3 (0.0–8.5) 6.8 (2.5–11.0) 3.9 (−1.3 to 9.0) 2.7 (−2.4 to 7.9)
p Value 0.048 0.002 0.14 0.30
MSQ-EF (range 0–100)
Baseline score, mean (SD) 52.4 (26.7) 55.6 (26.1) 57.7 (27.9) 53.8 (24.3) 50.8 (23.9) 55.4 (24.8)
Change from baseline 11.3 (7.9–14.8) 19.4 (15.3–23.5) 21.2 (17.1–25.4) 8.2 (4.2–12.2) 17.1 (12.3–21.9) 15.9 (11.1–20.7)
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A substantial proportion of patients who overused acute
medications at baseline transitioned to nonoveruse status,
regardless of the type of acute medication used. There was no
meaningful difference in the proportion of patients who
changed status over the full course of 3 months or during the
final 2 months of the double-blind phase, indicating an early
reduction in acute medication use. This early switch to non-
overuse status was supported by the number of patients with
nonoveruse status at month 1. It is not known whether this is
due to a decrease in the frequency of migraine days and im-
proved HRQOL or whether it was due to high patient
expectations of a new preventive treatment and reduced acute
medication intake in anticipation of clinical benefit. Although
not all patients changed to nonoveruse status, data from
a 1-year open-label extension study with erenumab demon-
strated a sustained reduction in acute migraine-specific
medication treatment days in the overall population.32
However, longer-term studies may be required to confirm the
durability of the effect on reduced medication overuse.
Similar to these results, previous studies have examined the
effect of migraine treatments, including topiramate and ona-
botulinumtoxinA, in patients with CM and medication over-
use. In the European topiramate CM trial, there was
a significant reduction in the mean number of MMD from
baseline compared with placebo within the medication over-
use subgroup of patients.26,27 In the onabotulinumtoxinA
analysis of pooled data from the PREEMPT trials, the efficacy
results in the medication overuse subgroup were similar to
those of the overall population with a significant reduction in
frequency of headache days and other headache symptom
measures, including PROs.16 However, the analysis of the
PREEMPT data did not include an analysis of the subgroup of
CM patients without medication overuse. These results, along
with the current study of erenumab, support that, contrary to
previous suggestions, headache preventive medications are
not necessarily limited by acute headache medication
overuse.2,33
The AE and tolerability profiles in the medication overuse
subgroup mirrored those observed for the full study pop-
ulation and were consistent with the safety and tolerability
profiles observed in multiple studies with erenumab in
patients with episodic and CM.15,34,35 Longer-term studies are
needed not just to determine the durability of the treatment
effect but also to assess long-term safety. Longer follow-up
periods in large numbers of patients are necessary to detect
rare AEs and to fully understand the safety profile of erenu-
mab. Particularly for patients with medication overuse, any
interactions with triptans are a concern. In vitro studies have
demonstrated that erenumab did not have an additive effect
on human coronary artery vasoconstriction induced by trip-
tans.36 Furthermore, there was no effect of combination
erenumab and sumatriptan on blood pressure compared to
sumatriptan alone in a phase 1 study.37 These studies, in
combination with the decrease in triptan use, indicate a lack of
effect of erenumab on the effectiveness of triptans as acuteTa
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migraine treatment, which one would expect triptan use to
increase.
Overall, these results demonstrate that erenumab is effective
in patients with CM and medication overuse with clinical
improvements in reduction of the frequency of migraines and
with improvements in PROs across multiple measures of
HRQOL, social and psychological impact, and disability in
patients with CM.
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